Basilea Pharmaceutica (OTCMKTS:BPMUF) Sets New 52-Week High – Should You Buy?

Basilea Pharmaceutica AG (OTCMKTS:BPMUFGet Free Report)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $72.66 and last traded at $72.66, with a volume of 11 shares changing hands. The stock had previously closed at $72.14.

Basilea Pharmaceutica Stock Performance

The company has a quick ratio of 5.67, a current ratio of 6.32 and a debt-to-equity ratio of 0.79. The business has a fifty day moving average of $63.99 and a 200 day moving average of $64.79.

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.

Featured Articles

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.